文献速递免疫规划传染病防控与疫情报告慢病防控与筛查

迈向实现乙型肝炎目标:格鲁吉亚2021年乙型肝炎流行病学及二十年疫苗接种的影响

Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021.
PubMed 文献 · Euro Surveill · 2023-01-01

格鲁吉亚2021年开展全国横断面血清学调查,采用多阶段分层整群设计,检测5岁及以上人群的乙型肝炎核心抗体(anti-HBc)及阳性者的乙型肝炎表面抗原(HBsAg)。5-17岁儿童HBsAg阳性率为0.03%(95%CI:0-0.19),成人HBsAg阳性率为2.7%(95%CI:2.3-3.4);儿童HBsAg阳性率远低于欧洲区域0.5%的控制目标,并达到≤0.1%的母婴传播消除目标。

要点

  • 5-17岁儿童HBsAg阳性率为0.03%(95%CI:0-0.19),anti-HBc阳性率为0.7%(95%CI:0.3-1.6)。
  • 成人HBsAg阳性率为2.7%(95%CI:2.3-3.4),anti-HBc阳性率为21.7%(95%CI:20.4-23.2)。
  • 18-23岁成人HBsAg阳性率最低(0.2%;95%CI:0.0-1.5),35-39岁最高(8.6%;95%CI:6.1-12.1)。

核心结论

  • 格鲁吉亚的乙型肝炎疫苗接种产生了显著影响,2021年儿童HBsAg阳性率远低于欧洲区域0.5%的控制目标,并达到≤0.1%的乙型肝炎母婴传播消除目标。
  • 慢性乙型肝炎病毒感染在疫苗引入前出生的成人中仍是问题,成人中的筛查、治疗和预防干预以及儿童持续高免疫覆盖率有助于格鲁吉亚到2030年消除乙型肝炎。

研究设计与样本

  • 2021年在格鲁吉亚≥5岁人群中开展的全国横断面血清学调查,采用多阶段分层整群设计。
  • 5-20岁参与者作为婴儿有资格接种乙型肝炎疫苗;血液样本检测anti-HBc,阳性者检测HBsAg;计算加权比例和95%置信区间(CI)。

主要发现

  • 5-17岁儿童(n=1,473)中,HBsAg阳性率为0.03%(95%CI:0-0.19),anti-HBc阳性率为0.7%(95%CI:0.3-1.6)。
  • 成人(n=7,237)中,HBsAg阳性率为2.7%(95%CI:2.3-3.4),anti-HBc阳性率为21.7%(95%CI:20.4-23.2)。
  • 成人中HBsAg阳性率在18-23岁最低(0.2%;95%CI:0.0-1.5),在35-39岁最高(8.6%;95%CI:6.1-12.1)。

关键数值与推荐

  • 欧洲区域乙型肝炎控制目标为儿童HBsAg阳性率<0.5%,格鲁吉亚2021年5-17岁儿童HBsAg阳性率为0.03%(95%CI:0-0.19)。
  • 乙型肝炎母婴传播消除目标为HBsAg血清阳性率≤0.1%,格鲁吉亚2021年5-17岁儿童HBsAg阳性率为0.03%(95%CI:0-0.19)。

临床怎么用

  • 作者认为,成人中的筛查、治疗和预防干预以及儿童持续高免疫覆盖率有助于格鲁吉亚到2030年消除乙型肝炎。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BackgroundGeorgia has adopted the World Health Organization European Region's and global goals to eliminate viral hepatitis. A nationwide serosurvey among adults in 2015 showed 2.9% prevalence for hepatitis B virus (HBV) surface antigen (HBsAg) and 25.9% for antibodies against HBV core antigen (anti-HBc). HBV infection prevalence among children had previously not been assessed.AimWe aimed to assess HBV infection prevalence among children and update estimates for adults in Georgia.MethodsThis nationwide cross-sectional serosurvey conducted in 2021 among persons aged ≥ 5 years used multi-stage stratified cluster design. Participants aged 5-20 years were eligible for hepatitis B vaccination as infants. Blood samples were tested for anti-HBc and, if positive, for HBsAg. Weighted proportions and 95% confidence intervals (CI) were calculated for both markers.ResultsAmong 5-17 year-olds (n = 1,473), 0.03% (95% CI: 0-0.19) were HBsAg-positive and 0.7% (95% CI: 0.3-1.6) were anti-HBc-positive. Among adults (n = 7,237), 2.7% (95% CI: 2.3-3.4) were HBsAg-positive and 21.7% (95% CI: 20.4-23.2) anti-HBc-positive; HBsAg prevalence was lowest (0.2%; 95% CI: 0.0-1.5) among 18-23-year-olds and highest (8.6%; 95% CI: 6.1-12.1) among 35-39-year-olds.ConclusionsHepatitis B vaccination in Georgia had remarkable impact. In 2021, HBsAg prevalence among children was well below the 0.5% hepatitis B control target of the European Region and met the ≤ 0.1% HBsAg seroprevalence target for elimination of mother-to-child transmission of HBV. Chronic HBV infection remains a problem among adults born before vaccine introduction. Screening, treatment and preventive interventions among adults, and sustained high immunisation coverage among children, can help eliminate hepatitis B in Georgia by 2030.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Khetsuriani N, Gamkrelidze A, Shadaker S, et al. Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021. Euro Surveill. 2023. PMID: 37498531. doi:10.2807/1560-7917.ES.2023.28.30.2200837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。